Flying High: China’s Eddingpharm Takes Another Step With Its First Global Licensing Deal

In its latest deal, Eddingpharm continues its march forward from a third-party promotional partner for companies like GSK, to a China-based specialty pharma. After in-licensing a string of compounds last year, it has now added three more from ACT Biotech.

More from China

More from Focus On Asia